Canada has a $94-billion opportunity to make medicines more affordable

We already know which patents are expiring—the country must move quickly and act on this $94-billion savings opportunity for Canadians. 
Over the next decade, hundreds of costly medicines will lose patent protection, opening the door to lower-cost versions. However, barriers could keep them from reaching Canadians for months or even years, writes Sandoz Canada's Michel Robidoux.

Over the next decade, hundreds of costly medicines will lose patent protection, opening the door to lower-cost versions. However, barriers could keep them from reaching Canadians for months or even years.

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.


By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MORE Opinion